A new model developed at Michigan Medicine at the University of Michigan in Ann Arbor could resolve one of the biggest challenges in prostate cancer treatment – distinguishing aggressive disease from slow-growing prostate cancer that is unlikely to spread.
The current method of evaluating prostate cancer risk, developed by the National Comprehensive Cancer Network, involves prostate-specific antigen (PSA) testing and tumor grading and staging. But this method, which has been used for decades, has several shortcomings.
The researchers used four multicenter, retrospective cohorts involving nearly 7,000 men to develop, test, and confirm the validity of the new model for assessing prostate cancer risk. They also created two new clinical systems for prostate cancer staging – a simple three-tiered system and a more complex six-tiered system. This research, which was published in the Journal of Clinical Oncology, could have significant implications for prostate cancer treatment.